NYSE:OGN - Organon & Co. Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $38.80
  • Forecasted Upside: 30.33 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$29.77
▲ +0.27 (0.92%)

This chart shows the closing price for OGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Organon & Co. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGN

Analyst Price Target is $38.80
▲ +30.33% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Organon & Co. in the last 3 months. The average price target is $38.80, with a high forecast of $48.00 and a low forecast of $33.00. The average price target represents a 30.33% upside from the last price of $29.77.

This chart shows the closing price for OGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Organon & Co..

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2021JPMorgan Chase & Co.Initiated CoverageNeutral$38.00Medium
6/11/2021Morgan StanleyInitiated CoverageEqual Weight$33.00Medium
6/10/2021Evercore ISIInitiated CoverageOutperformHigh
6/3/2021CowenInitiated CoverageMarket Perform$40.00Low
6/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$35.00Low
6/2/2021TruistInitiated CoverageBuy$48.00Low
(Data available from 6/24/2016 forward)
Organon & Co. logo
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
Read More

Today's Range

Now: $29.77
Low: $29.30
High: $30.07

50 Day Range

MA: N/A

52 Week Range

Now: $29.77
Low: $27.25
High: $38.75

Volume

2,768,273 shs

Average Volume

5,049,463 shs

Market Capitalization

$7.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Organon & Co.?

The following Wall Street research analysts have issued research reports on Organon & Co. in the last twelve months: Cowen Inc, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, The Goldman Sachs Group, Inc., and Truist.
View the latest analyst ratings for OGN.

What is the current price target for Organon & Co.?

5 Wall Street analysts have set twelve-month price targets for Organon & Co. in the last year. Their average twelve-month price target is $38.80, suggesting a possible upside of 31.5%. Truist has the highest price target set, predicting OGN will reach $48.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $33.00 for Organon & Co. in the next year.
View the latest price targets for OGN.

What is the current consensus analyst rating for Organon & Co.?

Organon & Co. currently has 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OGN, but not buy more shares or sell existing shares.
View the latest ratings for OGN.

What other companies compete with Organon & Co.?

Other companies that are similar to Organon & Co. include Chugai Pharmaceutical, Kyowa Kirin, Orion Oyj, PT Kalbe Farma Tbk. and Santen Pharmaceutical.

How do I contact Organon & Co.'s investor relations team?

The company's listed phone number is 551 430 6000. The official website for Organon & Co. is www.organon.com.